Krystal Biotech (KRYS) announced that on July 24, 2025, Japan’s Ministry of Health, Labour and Welfare, MHLW, granted marketing authorization to VYJUVEK for the treatment of wounds in patients with dystrophic epidermolysis bullosa, DEB, starting from birth. VYJUVEK is the first genetic medicine approved in Japan for the treatment of DEB and is designed to address the root cause of the disease by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing. The Japanese approval allows for dosing at home or in a healthcare setting, with the option for administration by patients or their family members.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Promising Phase 1 Results and Market Potential Drive Buy Rating for Krystal Biotech
- Krystal Biotech’s Promising Aesthetic Developments and Positive Phase I Results Justify Buy Rating
- Krystal Biotech’s Subsidiary Reports Positive Phase 1 Results
- Krystal Biotech subsidiary announces results from Phase 1 study of KB304
- Krystal Biotech price target lowered to $192 from $193 at BofA